Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dr. Matthieu CHAREYRE France

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

Website:
www.regulaxis.com
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Fundraising
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
CN109862905A published 2019-06-07 | Methods for treating osteoarthritis by administering linked variants of growth hormone and somatostatin | The present invention relates to the treatment of osteoarthritis. In particular, the present invention relates to peptides for use in the treatment of osteoarthritis
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1
Diagnostic companion kit OsteoArthritis
Medtech Development Stage
Slides Deck
(png, 430.99KB)
Dr. Matthieu CHAREYRE
Regulaxis
LinkedIn logo Chief Business Development Officer - Global Pharmaceutical Operations 
Functionality
Management

Cheng Charles United States

Knightway Capital is a global investment firm focusing on med-tech, fin-tech, and legal-tech investments. We commit people, knowledge, and capital to empower revolutionary ideas and help exceptional entrepreneurs build enterprises contributing to the common good and long-term prosperity of society.
​
We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
Website:
www.knightwaycapital.com
Partnering Objectives
Headquartner in China
No
Knightway Capital
Partner 

Mr Murthy Chavali India

Satya is an early-stage Oncology biotech focused on discovering small molecule NCEs, with novel targets against well-established Oncogenes, Tumor suppressors and Synthetic Lethal targets. Satya's team has over 50 years' combined discovery expertise, having worked on over 75 targets and delivered 15 clinical candidates
Website:
www.satyarx.com
Company Size (Fulltime employees)
11-50
Year of foundation
2019
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Satyarx Pharma Innovations Private Limited
LinkedIn logo CEO 
Functionality
Management

Nick Cheh China

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976. We have three main business segments: New Drug Development, Diagnostic Reagents, and Dietary Supplement .
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.
Website:
www.febico.com
Company Size (Fulltime employees)
51-200
Year of foundation
1990
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Asset Stage
Far East Bio-Tec. Co., Ltd
Director of BD 
Functionality
Business Development

Roby Chen China

Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.
Website:
en.humanwell.com.cn
Company Size (Fulltime employees)
5000+
Year of foundation
1993
Partnering Objectives
Please specify your partnering goal
See above
Headquartner in China
Yes
Humanwell Healthcare
投资部经理 

Tenghui Chen United States

Cancer Immunotherapy development
Website:
www.pepgenebio.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
PepGene Inc
CTO 

Kevin Chen China

Wuxi Xinwu District
Website:
Www.ICampus Wuxi.com
Partnering Objectives
Headquartner in China
Yes
Wuxi international life science innovation campus
Investment promotion manager 

Miss Ocean Chen China

Currently, TopWin Pharma. has developed to a high-tech group involving the biological and chemical medicine. TopWin Pharmaceutical Group's business has covered all aspects of R&D of new drugs, including clinical research, registration, production and sale. With the mission of "bringing benefits to mankind through innovation and technology", Topwin Group has been cooperating with well-known domestic and international drug R&D institutions to build TopWin Pharma. into a leading domestic and world-class pharmaceutical enterprise.
Website:
http://www.topwingroup.cn/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Oncology domain, clinical phase innovative project
Headquartner in China
Yes
Biotech/Pharma Category
Topwin pharma
BDM 

Suyuan Chen Germany

Our goal is to advance the development of analytical technologies by combining our specialist knowledge from chemistry, biology, physics and computer science and the transfer of our results to science, business and the public are our main goals.
Website:
https://www.isas.de/
Partnering Objectives
Headquartner in China
No
Leibniz-Institut fuer Analytische Wissenschaften - ISAS
Research associate 

Dr. Kai Chen United States

MID Labs has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, we have been instrumental in revolutionizing the ophthalmic field through our products.

MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Website:
midlabs.com
Company Size (Fulltime employees)
51-200
Year of foundation
30
Partnering Objectives
Please specify your partnering goal
marketing partner
Headquartner in China
No
Medtech Category
Medtech Information 1
Vitrectomy cutter||
Medtech Development Stage
MID LABS
CEO 
Functionality
Management